{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:17Z","timestamp":1793064197331,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00259-020-05078-1","type":"journal-article","created":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T04:27:51Z","timestamp":1603600071000},"page":"1487-1497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-8569","authenticated-orcid":false,"given":"A.","family":"Paschali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Panagiotidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Triantafyllou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Palaska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tsirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Verrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"\u03a5iannaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Markala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Papanikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Konstantinidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chatzipavlidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Katodritou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"5078_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ajh.25117","volume":"93","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:1091\u2013110.","journal-title":"Am J Hematol"},{"key":"5078_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/1078-0432.CCR-13-2159","volume":"20","author":"O Landgren","year":"2018","unstructured":"Landgren O, Morgan G. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice. Clin Cancer Res. 2018;20:804\u201313.","journal-title":"Clin Cancer Res"},{"key":"5078_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"5078_CR4","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538\u201348.","journal-title":"Lancet Oncol."},{"key":"5078_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/S1470-2045(17)30189-4","volume":"18","author":"M Cavo","year":"2017","unstructured":"Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:206\u201317.","journal-title":"Lancet Oncol."},{"key":"5078_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:328\u201346.","journal-title":"Lancet Oncol"},{"key":"5078_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/RLU.0000000000000773","volume":"40","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, et al. 18F-FDG dynamic PET\/CT in patients with multiple myeloma. Patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Clin Nucl Med. 2015;40:300\u20137.","journal-title":"Clin Nucl Med"},{"key":"5078_CR8","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ajh.25279","volume":"93","author":"MA Aljama","year":"2018","unstructured":"Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, et al. Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. Am J Hematol. 2018;93:1518\u201323.","journal-title":"Am J Hematol"},{"key":"5078_CR9","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TL, Shaughnessy JD Jr, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376.","journal-title":"Blood."},{"key":"5078_CR10","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","volume":"118","author":"E Zamagni","year":"2011","unstructured":"Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989\u201395.","journal-title":"Blood."},{"key":"5078_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bello M, et al. 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia. 2016;30:417\u201322.","journal-title":"Leukemia."},{"key":"5078_CR12","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","volume":"35","author":"P Moreau","year":"2017","unstructured":"Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, et al. Prospective evaluation of magnetic resonance imaging and [18 F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911\u20138.","journal-title":"J Clin Oncol"},{"key":"5078_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","volume":"130","author":"L Rasche","year":"2017","unstructured":"Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, et al. Low expression of hexokinase-2 is associated with false negative FDG-positron emission tomography in multiple myeloma. Blood. 2017;130:30\u20134.","journal-title":"Blood."},{"key":"5078_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","volume":"46","author":"Y Abe","year":"2019","unstructured":"Abe Y, Ikeda S, Kitadate A, Narita K, Kobayashi H, Miura D, et al. Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma. Eur J Nucl Med Mol Imaging. 2019;46:1345\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5078_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/17474086.2018.1537776","volume":"11","author":"D Ziogas","year":"2018","unstructured":"Ziogas D, Kastritis E, Dimopoulos MA. Prognostic factors for multiple myeloma in the era of novel agents. Expert Rev Hematol. 2018;11:863\u201379.","journal-title":"Expert Rev Hematol"},{"key":"5078_CR16","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.1999.17.5.1551","volume":"17","author":"SV Rajkumar","year":"1999","unstructured":"Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999;17:1551\u20137.","journal-title":"J Clin Oncol"},{"key":"5078_CR17","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0145-2126(99)00132-0","volume":"23","author":"JE Goasguen","year":"1999","unstructured":"Goasguen JE, Zandecki M, Mathiot C, Scheiff JM, Bizet M, Ly-Sunaram B, et al. Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res. 1999;23:1133\u201340.","journal-title":"Leuk Res"},{"key":"5078_CR18","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","volume":"43","author":"C Nanni","year":"2016","unstructured":"Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi MF, et al. Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5078_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","volume":"8","author":"LA Moulopoulos","year":"2018","unstructured":"Moulopoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018;8:95.","journal-title":"Blood Cancer J"},{"key":"5078_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s002560050423","volume":"27","author":"BC Vande Berg","year":"1998","unstructured":"Vande Berg BC, Malghem J, Lecouvet FE, Maldague B. Magnetic resonance imaging of the normal bone marrow. Skelet Radiol. 1998;27:471\u201383.","journal-title":"Skelet Radiol"},{"key":"5078_CR21","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1148\/rg.2016160056","volume":"36","author":"BY Chan","year":"2016","unstructured":"Chan BY, Gill KG, Rebsamen SL, Nguyen JC. MR imaging of pediatric bone marrow. RadioGraphics. 2016;36:1911\u201330.","journal-title":"RadioGraphics."},{"key":"5078_CR22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1259\/bjr\/21850180","volume":"81","author":"M Horger","year":"2008","unstructured":"Horger M, Pereira P, Claussen CD, Kanz L, Vonthein R, Denecke B, et al. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol. 2008;81:386\u201396.","journal-title":"Br J Radiol"},{"key":"5078_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bcmd.2003.12.001","volume":"32","author":"C Pellat-Deceunynck","year":"2004","unstructured":"Pellat-Deceunynck C, Bataille R. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis. 2004;32:293\u2013301.","journal-title":"Blood Cells Mol Dis"},{"key":"5078_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000203682","volume":"97","author":"H Papadaki","year":"1997","unstructured":"Papadaki H, Kyriakou D, Foudoulakis A, Markidou F, Alexandrakis M, Eliopoulos GD. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Acta Haematol. 1997;97:191\u20135.","journal-title":"Acta Haematol"},{"key":"5078_CR25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ctrv.2009.08.002","volume":"35","author":"E Katodritou","year":"2009","unstructured":"Katodritou E, Dimopoulos MA, Zervas K, Terpos E. Update on the use of erythropoiesis-stimulating agents (ESAs)for the management of anemia of multiple myeloma and lymphoma. Cancer Treat Rev. 2009;35:738\u201343.","journal-title":"Cancer Treat Rev"},{"key":"5078_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2967\/jnumed.118.217539","volume":"60","author":"S Kircher","year":"2019","unstructured":"Kircher S, Stolzenburg A, Kort\u00fcm KM, Kircher M, Da Via M, Samnick S, et al. Hexokinase-2 expression in 11C-methionine-positive, 18F-FDG-negative multiple myeloma. J Nucl Med. 2019;60:348\u201352.","journal-title":"J Nucl Med"},{"key":"5078_CR27","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca R, Blood EA, Oken AA, Kyle RA, Dewald GW, Baliy RJ, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735\u201341.","journal-title":"Blood."},{"key":"5078_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.clml.2020.01.018","volume":"20","author":"D Albano","year":"2020","unstructured":"Albano D, Treglia G, Gazilli M, Cerudelli E, Giubbini R, Bertagna F, et al. 18 F-FDG PET or PET\/CT in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20:422\u201330.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5078_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/bcj.2015.92","volume":"5","author":"AM Rajan","year":"2015","unstructured":"Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 2015;5:365.","journal-title":"Blood Cancer J."},{"key":"5078_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-017-3909-8","volume":"45","author":"C Nanni","year":"2018","unstructured":"Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET\/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45:712\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5078_CR31","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3390\/cancers12041030","volume":"12","author":"C Nanni","year":"2020","unstructured":"Nanni C. PET-FDG: Impetus. Cancers (Basel). 2020;12:1030.","journal-title":"Cancers (Basel)"},{"key":"5078_CR32","doi-asserted-by":"publisher","unstructured":"Zamagni E, Nanni, Dozza L, Carlier, Bailly C, Tacchetti P, et al. Standardization of 18F-FDG PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed transplant eligible multiple myeloma (MM) patients: joint analysis of two prospective randomized phase III trials. Blood 2018;132(Supplement 1):257-257.\u00a0https:\/\/doi.org\/10.1182\/blood-2018-99-111321.","DOI":"10.1182\/blood-2018-99-111321"},{"key":"5078_CR33","doi-asserted-by":"publisher","first-page":"4198673","DOI":"10.1155\/2018\/4198673","volume":"2018","author":"D Shengming","year":"2018","unstructured":"Shengming D, Bin Z, Zhou Y, Xu X, Li J, Sang S, et al. The role of 18F-FDG PET\/CT in multiple myeloma staging according to IMPeTUs: comparison of the Durie\u2013Salmon plus and other staging systems. Contrast Media Mol Imaging. 2018;2018:4198673. https:\/\/doi.org\/10.1155\/2018\/4198673.","journal-title":"Contrast Media Mol Imaging"},{"key":"5078_CR34","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.2967\/jnumed.112.106500","volume":"53","author":"R Fonti","year":"2012","unstructured":"Fonti R, Larobina M, Del Vecchio S, De Luca S, Fabbricini R, Catalano L, et al. Metabolic tumor volume assessed by 18F-FDG PET\/CT for the prediction of outcome in patients with multiple myeloma. J Nucl Med. 2012;53:1829\u201335.","journal-title":"J Nucl Med"},{"key":"5078_CR35","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1158\/1078-0432.CCR-16-0235","volume":"23","author":"JE McDonald","year":"2017","unstructured":"McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, et al. Assessment of total lesion glycolysis by 18F FDG PET\/CT significantly improves prognostic value of GEP and ISS in myeloma. Clin Cancer Res. 2017;23:1981\u20137.","journal-title":"Clin Cancer Res"},{"key":"5078_CR36","doi-asserted-by":"publisher","first-page":"16429","DOI":"10.1038\/s41598-019-52740-2","volume":"9","author":"MES Takahashi","year":"2019","unstructured":"Takahashi MES, Mosci C, Souza EM, Brunetto SQ, Etchebehere E, Santos AO, et al. Proposal for a quantitative 18 F-FDG PET\/CT metabolic parameter to assess the intensity of bone involvement in multiple myeloma. Sci Rep. 2019;9:16429. https:\/\/doi.org\/10.1038\/s41598-019-52740-2.","journal-title":"Sci Rep"},{"key":"5078_CR37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2214\/AJR.19.21283","volume":"213","author":"Y Abe","year":"2019","unstructured":"Abe Y, Narita K, Kobayashi H, Kitadate A, Takeuchi M, O'uchi T, et al. Medullary abnormalities in appendicular skeletons detected with 18 F-FDG PET\/CT predict an unfavorable prognosis in newly diagnosed multiple myeloma patients with high-risk factors. Am J Roentgenol. 2019;213:918\u201324.","journal-title":"Am J Roentgenol"},{"key":"5078_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.57","volume":"5","author":"Y Nishida","year":"2015","unstructured":"Nishida Y, Matsue Y, Suehara Y, Fukumoto K, Fujisawa M, Takeuchi M, et al. Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. Blood Cancer J. 2015;5:e329. https:\/\/doi.org\/10.1038\/bcj.2015.57.","journal-title":"Blood Cancer J"},{"key":"5078_CR39","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1182\/bloodadvances.2017014720","volume":"2","author":"K Matsue","year":"2018","unstructured":"Matsue K, Kobayashi H, Matsue Y, Abe Y, Narita K, Kitadate A, et al. Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma. Blood Adv. 2018;2:1032\u20139.","journal-title":"Blood Adv"},{"key":"5078_CR40","first-page":"89","volume":"19","author":"D Spira","year":"2012","unstructured":"Spira D, Weisel K, Brodoefel H, Schulze M, Kaufmann S, Horger M. Can whole-body low dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)? AcadRadiol. 2012;19:89\u201394.","journal-title":"AcadRadiol."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05078-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05078-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05078-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T10:19:54Z","timestamp":1635243594000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05078-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["5078"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05078-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,25]]},"assertion":[{"value":"10 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted, in accordance with the ethical principles laid down in the Declaration of Helsinki 2008 revision. The study was approved by the Ethics Committee of Theagenion Cancer Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and images.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}